sirolimus
information and resources from the National Cancer Institute
NCI Thesaurus | sirolimus
A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production. NCI Thesaurus | sirolimus
A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production.
|
|
|
|
news articles
Sirolimus-Releasing Stents More Effective Than VBT For Treating ... Mar 17, 2006
DG News ...with the SISR trial compared the use of vascular brachytherapy (VBT – intra-coronary radiation therapy) with implantation of the sirolimus-eluting stent for ...
Rapamycin (sirolimus) may be effective in treating kidney disease Mar 20, 2006
News-Medical.net, The drug is rapamycin, also called sirolimus, and is currently used as an immunosuppressant, to help prevent rejection of a new, transplanted kidney. ...
New Data Shows CYPHER Sirolimus-Eluting Coronary Stent Outperforms ... Mar 12, 2006
Trading Markets, ...company, said Sunday that Data from a multi-center, prospective randomized controlled clinical trial suggests that the CYPHER Sirolimus- eluting Coronary Stent ...
Four-Year Data Suggest the CYPHER(R) Sirolimus-eluting Coronary ... Mar 11, 2006
PR Newswire (press release), ATLANTA, March 11 /PRNewswire/ -- Patients treated with the CYPHER(R) Sirolimus-eluting Coronary Stent continued to experience significantly better long-term ...
Four-Year Data Suggest the CYPHER(R) Sirolimus-eluting Coronary ... Mar 11, 2006
PR Newswire (press release), Stent, According to New Study Results Presented at ACC 2006 ATLANTA, March 11 /PRNewswire/ -- Patients treated with the CYPHER(R) Sirolimus-eluting Coronary ...
Heart Attack Patients Fare Better With the CYPHER(R) Sirolimus ... Mar 13, 2006
PR Newswire (press release), ...as a Primary Treatment for Acute Myocardial Infarction is Presented at ACC 2006 ATLANTA, March 12 /PRNewswire/ -- The CYPHER(R) Sirolimus-eluting Coronary ...
Heart Attack Patients Fare Better With the CYPHER(R) Sirolimus ... Mar 12, 2006
Yahoo! News (press release) ATLANTA, March 12 /PRNewswire/ -- The CYPHER® Sirolimus-eluting Coronary Stent reduced the risk of target vessel failure (TVF) by almost half in patients who ...
New Clinical Data for the CYPHER(R) Sirolimus-Eluting Coronary ... Mar 8, 2006
PR Newswire (press release), ...and posters, clinical investigators will report on the first randomized trial clinical examining the use of the CYPHER(R) Sirolimus-eluting Coronary Stent in ...
Astellas Receives FDA Approval of Prograf(R) (Tacrolimus) for Use ... Mar 31, 2006
Yahoo! News (press release) In a 3-arm study conducted in the US, 331 patients received corticosteroids and Prograf plus sirolimus, Prograf plus mycophenolate mofetil (MMF) or ...
Four-Year Data Suggest the CYPHER(R) Sirolimus-eluting Coronary ... Mar 11, 2006
PR Newswire UK (press release), Patients treated with the CYPHER(R) Sirolimus-eluting Coronary Stent continued to experience significantly better long-term clinical outcomes than those who ...
Heart Attack Patients Fare Better With the CYPHER(R) Sirolimus ... Mar 12, 2006
PR Newswire UK (press release), The CYPHER(R) Sirolimus-eluting Coronary Stent reduced the risk of target vessel failure (TVF) by almost half in patients who suffered a heart attack (acute ...
Boston Scientific Reveals TAXUS Receives Favorable ACC Data With ... Mar 29, 2006
Trading Markets, ...a Cypher stent system. Cypher is a sirolimus-eluting stent while TAXUS is a paclitaxel-eluting stent. Among the study's diabetic ...
ACC Data Show Numerical Trend Favoring TAXUS(R) Coronary Stent ... Mar 29, 2006
Yahoo! News (press release) Research Institute at the Washington Hospital Center, Washington, DC, concluded that treating these patients with either a sirolimus-eluting stent (Cypher) or ...
Newly Published Data Suggest Better Outcomes With the CYPHER(R) ... Mar 12, 2006
PR Newswire (press release), MIAMI LAKES, Fla., March 12 /PRNewswire/ -- Data appearing today suggests that patients who received the CYPHER(R) Sirolimus-Eluting Coronary Stent had a ...
New Data Suggest Patients With Bifurcation Lesions Experienced ... Mar 13, 2006
PR Newswire (press release), ...a common vessel juncture and are often difficult to treat, experienced a low rate of serious events at six-months with the CYPHER(R) Sirolimus-eluting Coronary ...
Comparison of Drug-Releasing Coronary Stents Show Similar ... Mar 2, 2006
DG News CHICAGO, IL -- March 2, 2006 -- Use of coronary stents that release the drugs sirolimus or paclitaxel produced similar results in patients with new coronary ...
Brachytherapy for In-Stent Restenosis A Distant Second Choice to ... Mar 12, 2006
Journal of American Medical Association (subscription), ...of JAMA, Stone et al 17 and Holmes et al 18 report randomized comparisons of vascular brachytherapy vs a paclitaxel-eluting stent and a sirolimus-eluting stent ...
New Data Suggest Differences in Clinical Performance Between the ... Mar 12, 2006
Yahoo! News (press release) March 12 /PRNewswire/ -- Data from a multi-center, prospective randomized controlled clinical trial suggests that the CYPHER® Sirolimus- eluting Coronary ...
New Data Suggest Differences in Clinical Performance Between the ... Mar 12, 2006
PR Newswire UK (press release), Data from a multi-center, prospective randomized controlled clinical trial suggests that the CYPHER(R) Sirolimus-eluting Coronary Stent outperformed the Taxus ...
Newly Published Data Suggest Better Outcomes With the CYPHER(R) ... Mar 12, 2006
PR Newswire UK (press release), Data appearing today suggests that patients who received the CYPHER(R) Sirolimus-Eluting Coronary Stent had a significantly lower incidence of target vessel ...
Drug-Releasing Stents More Effective Than Radiation Mar 13, 2006
Ivanhoe, In the second study, researchers from the Mayo Clinic, Rochester, Minn., compared VBT use with a sirolimus-releasing stent to treat restenosis from a ...
Stent Registry Safety Data Favors Taxus® Over Cypher® In The ... Mar 18, 2006
Medical News Today (press release), ...“Previous studies have confirmed that paclitaxel and sirolimus have different mechanisms of action, and this study provides additional favorable data ...
Drug-Coated Stents Beat Radiation at Reopening Arteries Mar 12, 2006
Forbes Each study was financed by one of the companies that market coated stents -- Johnson & Johnson, whose stents are coated with sirolimus; and Boston Scientific ...
Drug-Coated Stents Beat Radiation at Reopening Arteries Mar 12, 2006
HealthCentral.com Each study was financed by one of the companies that market coated stents -- Johnson & Johnson, whose stents are coated with sirolimus; and Boston Scientific ...
ACC: Taxus Stent Beats Radiation for Treating InStent Restenosis Mar 12, 2006
MedPage Today, In the SISR trial with the Cypher sirolimus-eluting stent, reported here as well, those who received the stent had about half the rate of target vessel failure ...
Drug-eluting and absorbable stents push interventional frontiers Mar 13, 2006
EurekAlert (press release), The Cypher stent slowly releases sirolimus, a medication that prevents the overgrowth of scar tissue that can cause restenosis in the months after stenting. ...
Studies compare stents and cardiac procedures for long-term ... Mar 14, 2006
EurekAlert (press release), ...and Medical College of Virginia in Richmond, used the pooled results of 15 independent head-to-head trials to compare the efficacy of sirolimus-eluting stents ...
Drug-coated stents can help treat reblocked arteries: study Mar 12, 2006
MarketWatch ..."This study suggests that the sirolimus-eluting stent is a safe and effective treatment for in-stent ... Sirolimus is the drug that coats the Cypher stent. ...
Drug-coated stents work where older stents failed Mar 13, 2006
Reuters.uk, Two clinical studies indicate that inserting a stent covered with the drug paclitaxel or sirolimus inside the old clogged stent reduces the risk of the vessel ...
STENT Registry Safety Data Favors TAXUS(R) Over Cypher(R) in the ... Mar 12, 2006
Boursorama, ..."Previous studies have confirmed that paclitaxel and sirolimus have different mechanisms of action, and this study provides additional favorable data regarding ...
SurModics Completes Enrollment of Phase I Clinical Trial of the I ... Mar 20, 2006
Genetic Engineering News, ...many drug delivery polymer matrix technologies, including the Bravo(TM) polymer matrix, which is currently used on the Cypher(R) Sirolimus-Eluting Coronary ...
(PRN) - Following Is a Test Release ... [+] Mar 12, 2006
Bolsamania.com, ...[+]. (PRN) - New Data Suggest Differences in Clinical Performance Between the CYPHER(R) Sirolimus-Eluting Coronary Stent and the Taxus Stent in Long Complex ...
Stenting just the left main stem gives equivalent results Mar 18, 2006
RxPG NEWS, Dr. Steigen will present the results of the "Main Vessel and Side Branch Stenting versus Optional Side Branch Stenting Using Sirolimus-Eluting Stents in ...
Stent Repair: Coated replacements better than radiation Mar 17, 2006
Science News Only 9 percent and 11 percent of stents laced with the drugs sirolimus (Rapamycin) and paclitaxel (Taxol), respectively, needed to be reopened during the two 9 ...
STENT registry safety data favors TAXUS(R) over Cypher(R) in the ... Mar 12, 2006
CNW Telbec (Communiqués de presse), ...enrollment to further investigate this apparent difference in outcomes." "Previous studies have confirmed that paclitaxel and sirolimus have different ...
Examining stenting options in diabetics Mar 13, 2006
RxPG NEWS, Dr. Simonton and the STENT Group of eight coronary intervention centers have examined how the sirolimus-eluting (SES) and paclitaxel-eluting stents (PES ...
Stents that save lives Feb 25, 2006
Malaysia Star, ...agents. By their very nature, they either stop cells from multiplying (like sirolimus) or they kill cells (like paclitaxel). As ...
(PRN) - PMC Commercial Trust Announces First Quarter Dividend of ... Mar 13, 2006
Bolsamania.com, ...[+]. (PRN) - New Data Suggest Patients With Bifurcation Lesions Experienced Very Low Serious Event Rates With The CYPHER(R) Sirolimus-Eluting Coronary Stent ... ...
Study boosts J&J's stent Mar 15, 2006
Pioneer Press, ...obstruction. They theorized that the sirolimus drug coating on the Cypher is more potent than the paclitaxel medicine used on the Taxus. ...
Boston Scientific to Release Broad Range of Clinical Study Results ... Mar 7, 2006
Finanzen.net, This large, independent, prospective, mulitcenter registry evaluates the comparative late clinical outcomes of paclitaxel- and sirolimus-eluting coronary ...
Stents as effective as bypass surgery Mar 14, 2006
United Press International In a separate study, US, Italian and Belgian researchers said so-called sirolimus-eluting stents -- those treated with a drug that suppresses the immune system ...
Drug-eluting stents help diabetics Mar 13, 2006
United Press International Charles Simonton of the Carolinas Medical Center, Charlotte, NC, and doctors from eight coronary intervention centers examined how the sirolimus-eluting (SES ...
New Hope Seen in Cell Transplants for Diabetes Patients Feb 26, 2006
AXcess News, ...that, the researchers administered an anti-IL-2 receptor and anti-CD154 (H106) antibody, while maintaining immunosuppression using sirolimus and belatacept (a ...
Mass spec cuts costs for routine drug monitoring Feb 27, 2006
Laboratory Talk, ...we developed a very elegant tandem MS method for the simultaneous determination of various immunosuppressive drugs such as sirolimus, everolimus, tacrolimus ...
CYPHER(R) Sirolimus-eluting Coronary Stent Benefits From Clinical ... 21 Dec 2005
PR Newswire (press release), Scientific Sessions found that patients with bifurcation lesions fared significantly better when treated with the CYPHER(R) Sirolimus-eluting Coronary Stent ...
(PRN) - Hampton Roads Sanitation District Selects Datastream 7i to ... 21 Dec 2005
Bolsamania.com, Teachers ... [+. PRN) - CYPHER(R) Sirolimus-eluting Coronary Stent Benefits From Clinical Success, Worldwide Growth in 2005 ... [+. ...
Sirolimus and Tacrolimus Without Methotrexate Appear Promising for ... Dec 12, 2005
DG News ATLANTA, GA -- December 12, 2005 -- Immunosupressants sirolimus (Rapamycin) and tacrolimus (Prograf) used without methotrexate appear to improve the odds for ...
Incremental Reimbursement Granted in France for the CYPHER(R) ... Dec 14, 2005
Biotech Intelligence (press release), The CYPHER SELECT(TM) Sirolimus-eluting Coronary Stent, which is the first next generation drug-eluting stent, was launched in Europe, Asia Pacific, Latin ...
(PRN) - Reveleus Selected by Lloyds TSB's Securitisation Team to ... Dec 14, 2005
Bolsamania.com, PRN) - Incremental Reimbursement Granted in France for the CYPHER(R)Sirolimus-eluting Coronary Stent and CYPHER SELECT(TM) Sirolimus-eluting Coronary Stent ... ...
Italian Ministry of Health Assigns Higher Price Premium to Cypher ... Dec 1, 2005
PharmaLive.com (press release), Cordis Corporation today announced that Italy's Ministry of Health has established a higher price premium for the CYPHER(R) Sirolimus-eluting Coronary Stent ...
TAXUS(TM) Stent Demonstrates Excellent Efficacy and Safety in ... Nov 29, 2005
Finanzen.net, ...have completed 9-months of follow-up to date revealed a numerical trend favouring the TAXUS stent over Johnson & Johnson's Cypher(R) sirolimus-eluting stent ...
Axis-Shield 2005 pre-close trading update Axis-Shield Dec 16, 2005
Biotech Intelligence (press release), In particular good growth was achieved on the AxSYM® BNP heart failure marker and thyroid marker tests and the IMx® sirolimus test, needed to monitor blood ...
Coronary Angioplasty Nov 30, 2005
Pinoy Monthly, A new stent, coated with sirolimus (rapamycin), has been reported June 6, 2002 in the New England Journal of Medicine as being much superior to the currently ...
(PRN) - University of Virginia Health System to Implement ... Dec 1, 2005
Bolsamania.com, Orphans ... [+. PRN) - Italian Ministry of Health Assigns Higher Price Premium to Cypher(R) Sirolimus-Eluting Coronary Stent ... [+.
Invasive aspergillosis survival, Voriconazole may be better than ... Nov 19, 2005
Xagena.it, ...since increased plasma concentrations for these drugs can lead to QT prolongation and rare occurrences of torsades de pointes ), Sirolimus, Rifampin, Rifabutin ...
|
|
